A low serum VEGF level has been found to predict the AD persistence in infancy [44], while the enzyme indoleamine 2,3-dioxygenase-1 (IDO1) has been proposed as a prognostic candidate biomarker for the development of eczema herpeticum and other viral complications in AD patients [82]. This evidence concerns the gene VEGFA and herpes simplex dermatitis.